Vaxart (VXRT, Financial) has released a video update featuring Dr. Sean Tucker, aimed at providing information to stockholders. The video can be accessed on the company’s investor relations page at investors.vaxart.com. In this update, Dr. Tucker encourages shareholders to support Proposal No. 2. This proposal seeks to authorize the Board of Directors to execute a reverse stock split. The move is intended to assist Vaxart in meeting Nasdaq's minimum bid price requirements.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Vaxart Inc (VXRT, Financial) is $4.67 with a high estimate of $8.00 and a low estimate of $2.00. The average target implies an upside of 937.04% from the current price of $0.45. More detailed estimate data can be found on the Vaxart Inc (VXRT) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Vaxart Inc's (VXRT, Financial) average brokerage recommendation is currently 1.3, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Vaxart Inc (VXRT, Financial) in one year is $76.81, suggesting a upside of 16968.89% from the current price of $0.45. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Vaxart Inc (VXRT) Summary page.
VXRT Key Business Developments
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Vaxart Inc (VXRT, Financial) successfully lifted the stop work order on their 10,000 participant COVID-19 Phase 2B vaccine trial, indicating progress in their clinical development.
- The company completed enrollment in their Phase 1 norovirus vaccine trial, showing efficiency in advancing their clinical programs.
- Vaxart Inc (VXRT) reported a significant increase in revenue for Q1 2025, primarily due to their BARDA contract, indicating strong financial performance.
- The company is actively pursuing strategic partnerships, which could provide non-dilutive funding and further advance their vaccine programs.
- Vaxart Inc (VXRT) has a new CFO, Jerome Grossman, who brings over 20 years of experience in biotech, potentially strengthening their financial leadership.
Negative Points
- Vaxart Inc (VXRT) faced a stop work order on their COVID-19 trial, which caused delays in their clinical timeline.
- The company had to implement workforce reductions to manage costs, indicating financial constraints.
- Vaxart Inc (VXRT) is at risk of being delisted from NASDAQ due to not meeting the $1 minimum bid price requirement, which could impact their stock liquidity and investor interest.
- The resignation of their CFO, Phil Lee, for personal reasons, may cause transitional challenges in their financial management.
- The company is considering a reverse stock split as a last resort to maintain NASDAQ listing, which could affect shareholder value.
